Announcements Trials

Browse Landscape

Phase

Phase 2 8 Phase 3 3 Phase NA 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Vomiting 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Nausea 1 Lung Neoplasms 1 Klatskin Tumor 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 97 130-nm albumin-bound paclitaxel 47 Albumin-Bound Paclitaxel 36 Oxaliplatin 27 Fluorouracil 26 Capecitabine 20 Taxes 19 Leucovorin 19 pembrolizumab 18 Cyclophosphamide 18 Irinotecan 16 Bevacizumab 12 fludarabine 11 Nivolumab 11 Cetuximab 11 Cisplatin 10 durvalumab 8 Radiotherapy 8 spartalizumab 7 aldesleukin 7 Erlotinib Hydrochloride 7 Drug Therapy 7 avelumab 6 Radiosurgery 6 Paclitaxel 6 irinotecan sucrosofate 5 folfirinox 5 Ipilimumab 5 Injections 5 ALT-803 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Neoplasms × Neoadjuvant Therapy × Clear all

NCT02305186 2021-08-13

UVA-PC-PD101

University of Virginia

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡